This Biosynthesis Intermediates Stock Rises 56% in 6 Months: From 52-Week Low to Global CDMO Deal Maker
- September 24, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Gujarat Themis Biosyn share price rose from around Rs 264 to about Rs 412 in six months, up approximately 56%, after a Rs 1,300 crore Japan acquisition closed in September 2026.
Quick Answer
This biosynthesis intermediates stock, Gujarat Themis Biosyn, has risen approximately 56% in six months, from around Rs 264 on 24 March 2026 to about Rs 412 on 24 September 2026. The rally followed the Rs 1,300 crore acquisition of Japan’s MicroBiopharm, a Sanofi anti-TB brand portfolio deal, and improving quarterly margins. The one-year return is close to flat, so this is largely a recovery from an earlier drawdown rather than a fresh breakout.
This biosynthesis intermediates stock has rallied 56% in six months, turning a beaten-down small-cap pharma name into one of the more talked-about recovery stories on Dalal Street. The move has come on real operational triggers rather than pure momentum, and this biosynthesis intermediates stock now trades close to its 52-week high after spending early 2026 near its 52-week low.
The company behind this biosynthesis intermediates stock is Gujarat Themis Biosyn Ltd, a Vadodara-based manufacturer of Vitamin B1 (thiamine) and other biosynthesis-based fermentation products, run as a joint venture with promoter group company Themis Medicare Limited. Gujarat Themis Biosyn share price has moved from around Rs 264 in late March 2026 to nearly Rs 412 now, a period marked by a large overseas acquisition, a new brand portfolio deal, and a capital raise funding its next phase of growth. That combination defines this biosynthesis intermediates stock heading into FY27.
Click Here – Get Free Investment Predictions
Biosynthesis Intermediates Stock: 6-Month and 1-Year Return Snapshot
Gujarat Themis Biosyn share price closed at approximately Rs 264.35 on 24 March 2026 and traded around Rs 411.95 on 24 September 2026, a verified gain of approximately 56% in six months, placing this biosynthesis intermediates stock among the stronger names on a screen of NSE small-cap stocks ranked by 6-month return, dated 24 September 2026. Few 6-month movers on the small-cap screen matched this pace.
How the Six-Month Move Compares With Longer Periods
The six-month number looks impressive on its own, but the one-year comparison tells a more honest story. Gujarat Themis Biosyn share price on 24 September 2025 was approximately Rs 411.65, almost identical to the current price. This biosynthesis intermediates stock has mostly round-tripped over twelve months for this biosynthesis intermediates stock: it fell hard into March 2026 and has since recovered most of that drawdown, rather than climbing to a fresh high.
| Period | Return | Gujarat Themis Biosyn Share Price Reference |
|---|---|---|
| 6 Months (24 Mar 2026 to 24 Sep 2026) | approximately +56% | Rs 264.35 to Rs 411.95 |
| 1 Month (24 Aug 2026 to 24 Sep 2026) | approximately flat | Rs 411.70 to Rs 411.95 |
| 1 Year (24 Sep 2025 to 24 Sep 2026) | approximately flat | Rs 411.65 to Rs 411.95 |
| 52-Week Range | Rs 225.05 to Rs 479.00 | Current price near mid-to-upper range |
Why Is This Biosynthesis Intermediates Stock Rallying Right Now?
The rally in this biosynthesis intermediates stock is tied to dated, company-specific events, not a general small-cap rally: an overseas acquisition that changes its business model, a branded portfolio deal, and a capital raise funding both. Each has a specific date and number attached to it, which is unusual for a stock this size. Understanding these triggers matters, since this biosynthesis intermediates stock could give back gains quickly if any of them disappoints.
The MicroBiopharm Japan Acquisition
On 18 September 2026, Gujarat Themis Biosyn completed the acquisition of MicroBiopharm Japan Co Ltd for approximately Rs 1,300 crore (around JPY 21.5 billion), funded through roughly Rs 475 crore of equity and Rs 745 crore of debt. MicroBiopharm Japan runs three GMP plants in precision fermentation, plasmid DNA and antibody-drug conjugate work, serving six global clients for two decades. Management called the deal earnings accretive, the single biggest reason this biosynthesis intermediates stock has re-rated in 2026.
The Sanofi Anti-TB and Anti-Infectives Portfolio
Alongside the Japan deal, the company is acquiring 13 established anti-tuberculosis and anti-infective brands from Sanofi, valued at approximately EUR 158 million, adding distribution access across more than 55 countries. For a company whose core business has been fermentation-based intermediates sold largely to formulators, owning finished branded products in regulated and emerging markets is a genuine strategic shift. This biosynthesis intermediates stock is no longer a pure fermentation supplier.
Q1 FY27 Results and Margin Expansion
Results for the quarter ended 30 June 2026, announced on 7 August 2026, showed revenue of approximately Rs 43.9 crore, up about 22% year on year, with EBITDA of approximately Rs 20.9 crore and an EBITDA margin of 47.8%, up sharply from 39.6% a year earlier. Net profit rose to approximately Rs 11.1 crore from Rs 9.1 crore, a margin trend long-term holders of this biosynthesis intermediates stock watch closely before any re-rating in this biosynthesis intermediates stock.
A Rs 1,000 Crore QIP to Fund Growth
Shareholders approved a qualified institutional placement of up to Rs 1,000 crore on 13 July 2026, with 99.98% of votes in favour, for prepaying borrowings, subsidiary investments, capital expenditure and further acquisitions. This is the direct reason promoter shareholding fell from around 70.9% in June 2026 to about 59.3% in August 2026, since new institutional equity dilutes the existing base. A fermentation capacity expansion also became fully operational by end-August 2026, adding to the volume growth story that now defines this biosynthesis intermediates stock. That capacity add underpins this biosynthesis intermediates stock’s next leg of growth.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Gujarat Themis Biosyn Share Price: Quarterly and Annual Financials
The quarterly numbers show a business that has been improving steadily through FY26 and into FY27, with margins expanding faster than revenue. Annual numbers show a company that dipped in FY25 before recovering in FY26, ahead of the current wave of acquisitions. Both data sets are essential context for anyone pricing this biosynthesis intermediates stock today, since this biosynthesis intermediates stock has re-rated on execution, not hope. Few small-cap names have re-rated this fast.
| Quarter | Revenue (Rs Cr) | EBITDA (Rs Cr) | EBITDA Margin | Net Profit (Rs Cr) |
|---|---|---|---|---|
| Q1 FY26 (Jun 2025) | 36.1 | 14.2 | 39.6% | 9.1 |
| Q4 FY26 (Mar 2026) | 45.2 | 20.3 | 45.9% | 10.9 |
| Q1 FY27 (Jun 2026) | 43.9 | 20.9 | 47.8% | 11.1 |
Annual numbers show the multi-year picture: revenue was approximately Rs 148 crore in FY23, Rs 170 crore in FY24, Rs 151 crore in FY25 and Rs 166 crore in FY26, with net profit of Rs 58 crore, Rs 59 crore, Rs 49 crore and Rs 47 crore in those years, and operating margins holding between 46% and 50%.
On valuation, Gujarat Themis Biosyn trades at a trailing PE of approximately 109.6 against an industry PE of approximately 51.6, a price to book of approximately 5.1, and a return on equity of approximately 16.2%, with a market capitalisation of approximately Rs 5,337 crore. Debt to equity stood at approximately 0.56 after the MicroBiopharm Japan debt. This is a richly valued biosynthesis intermediates stock relative to its sector, and it will need consistent earnings delivery to justify that premium.
Gujarat Themis Biosyn Shareholding Pattern: Who Owns the Stock?
Promoter holding stood at approximately 59.3% as of August 2026, down from approximately 70.9% in the March and June 2026 quarters, entirely on account of QIP dilution rather than promoter selling. Institutional interest has picked up alongside the deal-making: FII holding rose to approximately 4.9% and DII holding to approximately 13.8% in August 2026, up from roughly 1.8% and 1.2% respectively in March 2026, with Quant Mutual Fund among the larger disclosed holders. Public shareholding was approximately 22% in August 2026. Institutions have taken a fresh look at this biosynthesis intermediates stock.
| Category | Sep 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|
| Promoters | 70.9% | 70.9% | 70.9% | 59.3% |
| FII | 3.0% | 1.8% | 1.8% | 4.9% |
| DII | 1.2% | 1.2% | 1.2% | 13.8% |
| Public | 25.0% | 26.2% | 26.2% | 22.0% |
Key Risks for This Biosynthesis Intermediates Stock
Four risks stand out for anyone tracking this biosynthesis intermediates stock beyond the headline six-month return, and this biosynthesis intermediates stock is not free of them. First, integration risk: the MicroBiopharm Japan and Sanofi brand deals both closed or were announced within the past few months, and folding a Japanese GMP manufacturer and a multi-country branded portfolio into a company of this size is operationally demanding, with real currency, regulatory and cultural execution risk.
Second, dilution and balance sheet risk: the approved Rs 1,000 crore QIP and the debt taken on for the Japan acquisition mean earnings per share growth needs to outpace new equity issuance and higher interest costs for the re-rating to hold. Third, promoter and related-party concentration: Gujarat Themis Biosyn operates as a joint venture with Themis Medicare, and promoter group entities had pledged shares against loans in 2026, mostly released in July after repayment, a history worth watching as fresh debt again funds acquisitions. This biosynthesis intermediates stock carries more balance sheet risk than a year ago.
Fourth, small-cap liquidity and volatility risk applies directly here. Daily volumes can swing sharply, the stock moved from a 52-week low of Rs 225.05 to a high of Rs 479 within the same year, and a stock near 110 times trailing earnings can correct quickly if integration milestones slip. Investors should size positions in this biosynthesis intermediates stock with that volatility in mind rather than assuming the six-month trend continues in a straight line.
Download the Univest iOS App or Univest Android App to track the Gujarat Themis Biosyn share price live
Gujarat Themis Biosyn Share: Analyst View
Gujarat Themis Biosyn Share Price Target
No verified brokerage target for Gujarat Themis Biosyn share price target was found, using levels and earnings instead. The stock trades around Rs 412, between its 52-week high of Rs 479 and low of Rs 225.05, making the high the level to watch. A move above Rs 479 would put this biosynthesis intermediates stock in fresh territory, while a slip toward Rs 350-380 would flag integration concerns. Given a valuation of roughly 109.6 times trailing earnings against an industry PE near 51.6, any Gujarat Themis Biosyn share price target investors form should lean on FY27 execution, not FY26 numbers.
Other Stocks to Track From the Same Return Screen
Beyond this biosynthesis intermediates stock, a screen of NSE small-cap stocks ranked by recent returns also includes related names such as Kwality Wall’s (India) Ltd with a 6-month return of 73.51%, AGI Greenpac at 71.50% and eMudhra at 65.84%.
Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this biosynthesis intermediates stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.
Conclusion
This biosynthesis intermediates stock has delivered a genuine 56% gain over six months, built on a large overseas acquisition, a branded portfolio deal, improving margins and a capital raise, not speculative momentum alone. At the same time, the one-year return is close to flat, valuations are demanding relative to the sector, and integration and dilution risks are real for this biosynthesis intermediates stock. Investors considering Gujarat Themis Biosyn share price levels from here should track MicroBiopharm and Sanofi integration over the next two to three quarters, not just the last six months.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is this biosynthesis intermediates stock that rose 56% in six months?
Ans. It is Gujarat Themis Biosyn Ltd (NSE: GUJTHEM), a Vadodara-based manufacturer of Vitamin B1 and other biosynthesis-based fermentation products that operates as a joint venture with Themis Medicare Limited. Its share price rose from around Rs 264 to about Rs 412 between 24 March 2026 and 24 September 2026. This is an actively discussed biosynthesis intermediates stock in the small-cap pharma space.
Why did Gujarat Themis Biosyn share price rise so much in six months?
Ans. The rally followed the Rs 1,300 crore acquisition of Japan’s MicroBiopharm, a Sanofi anti-TB and anti-infectives brand portfolio deal worth approximately EUR 158 million, and a Q1 FY27 EBITDA margin that expanded to 47.8%. A Rs 1,000 crore QIP approved in July 2026 funded much of this expansion. These triggers are dated and verifiable, which is why this biosynthesis intermediates stock has re-rated.
What is the Gujarat Themis Biosyn share price target from analysts?
Ans. No verified brokerage target was available as of this writing. The stock trades around Rs 412, between its 52-week low of Rs 225.05 and 52-week high of Rs 479, so the 52-week high is the nearest technical level to watch. Treat any target for this biosynthesis intermediates stock as unofficial until confirmed.
Is Gujarat Themis Biosyn share price expensive right now?
Ans. Yes, on standard valuation metrics. It trades at a trailing PE of approximately 109.6 against an industry PE of around 51.6 and a price to book of about 5.1, which is high for the sector and leaves little room for execution missteps. That gap is why some see this biosynthesis intermediates stock as fully priced.
Why did Gujarat Themis Biosyn promoter shareholding fall in 2026?
Ans. Promoter holding fell from approximately 70.9% to about 59.3% between June and August 2026 because of dilution from the Rs 1,000 crore QIP approved by shareholders, not because promoters sold shares in the open market. The percentage drop alone is not a negative signal for this biosynthesis intermediates stock.
Has Gujarat Themis Biosyn share price gained over the last one year, not just six months?
Ans. Not meaningfully. The one-year return to 24 September 2026 is close to flat, since the stock fell sharply into March 2026 before recovering, so the six-month gain is largely a round trip back to year-ago levels rather than a fresh all-time high. That matters when comparing this biosynthesis intermediates stock against pure momentum names.
What are the key risks in Gujarat Themis Biosyn share price today?
Ans. The main risks are integration risk on the newly closed MicroBiopharm Japan and Sanofi deals, dilution and higher debt from the QIP and acquisition financing, promoter and related-party concentration through the Themis Medicare joint venture, and small-cap liquidity and volatility given the stock’s wide 52-week range. Together, these keep this biosynthesis intermediates stock a higher-volatility small-cap bet.
Has Gujarat Themis Biosyn share price hit a new 52-week high recently?
Ans. Not yet. The stock has traded up to Rs 479 in the past year but was around Rs 412 as of 24 September 2026, still below that 52-week high, after recovering from a 52-week low of Rs 225.05 earlier in 2026. The 52-week high stays the key level to watch here. That level matters most for this biosynthesis intermediates stock right now.
